Mortality, Length of Stay, and Cost Associated with Hospitalized Adult Cancer Patients with Febrile Neutropenia |
Chindaprasirt, Jarin
(Division of Oncology, Faculty of Medicine, Khon Kaen University)
Wanitpongpun, Chinadol (Division of Hematology, Faculty of Medicine, Khon Kaen University) Limpawattana, Panita (Division of Geriatric Medicine, Internal Medicine Department, Faculty of Medicine, Khon Kaen University) Thepsuthammarat, Kaewjai (Clinical Epidemiology Unit, Faculty of Medicine, Khon Kaen University) Sripakdee, Warunsuda (Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University) Wirasorn, Kosin (Division of Oncology, Faculty of Medicine, Khon Kaen University) Sookprasert, Aumkhae (Division of Oncology, Faculty of Medicine, Khon Kaen University) |
1 | Bodey GP, Buckley M, Sathe YS, et al (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med, 64, 328-40. DOI ScienceOn |
2 | Chindaprasirt J, Sookprasert A, Wirasorn K, et al (2012). Cost of colorectal cancer care in hospitalized patients of Thailand. J Med Assoc Thai, 95, 196-200. |
3 | Courtney DM, Aldeen AZ, Gorman SM, et al (2007). Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. The Oncologist, 12,19-26. |
4 | Ellis M (2008). Febrile neutropenia evolving strategies. Ann N Y Acad Sci, 1138, 329-50. DOI ScienceOn |
5 | Elting LS, Lu C, Escalante CP, et al (2008). Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol, 26, 606-11. DOI ScienceOn |
6 | Hollenberg CH (1996). The effect of health care reform on academic medicine in Canada. Editorial committee of the Canadian institute for academic medicine. CMAJ, 154, 1483-9. |
7 | Innes H, Lim SL, Hall A, et al (2008). Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer, 16, 485-91 . DOI ScienceOn |
8 | Jin J, Lee YM, Ding Y, et al (2010). Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore. Ann Acad Med Singapore, 39, 453-9. |
9 | Kuderer NM, Dale DC, Crawford J, et al (2006). Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-66. DOI ScienceOn |
10 | Lal A, Bhurgri Y, Rizvi N, et al (2008). Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. Asian Pac J Cancer Prev, 9, 303-8. |
11 | Liou SY, Stephens JM, Carpiuc KT, et al (2007). Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig, 27, 381-96. DOI ScienceOn |
12 | Teuffel O, Amir E, Alibhai S, et al (2011). Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer, 26, 1377-83. |
13 | Schelenz S, Giles D, Abdallah S (2012). Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol, 23, 1889-93. DOI ScienceOn |
14 | Schilling MB, Parks C, Deeter RG (2011). Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med, 2, 859-66. |
15 | Stokes ME, Muehlenbein CE, Marciniak MD, et al (2009). Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm, 15, 669-82. |